Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
The multi-country footprint of the included trials supports our rationale that ethnicity-sensitive eligibility criteria, rather than a single fixed BMI threshold, may be needed to support equitable representation across populations whose anthropometric and metabolic profiles differ from the reference frames historically used to design these trials
Looking Ahead As the demand for GLP-1 agonists continues to grow, its crucial to stay informed about their availability, safety considerations, and regulatory guidelines
This is because there is not enough safety data to know whether taking a GLP-1 medicine can cause harm to the baby. Similar warnings are present in patient information leaflets
Study population and exposure The study population comprised adults (18 years) with diagnosed MASLD who initiated either combination therapy (GLP-1RAs plus SGLT2i) or monotherapy (SGLT2i alone) between January 2017 and October 2024
How do I stay motivated when progress slows
US$ 24.20
US$ 24.93
US$ 20.40
US$ 23.91
US$ 21.62
US$ 27.05
US$ 21.41
US$ 23.69
